Skip to main navigation Skip to search Skip to main content

Olaparib-Cediranib Hybrid as Dual PARP-VEGFR3 Inhibitor Elicits Antitumor Efficacy: Rational Design, Synthesis, Biological Evaluation and Construction of a Charge Convertible pH Responsive Nanoformulation

  • Mandeep Rana
  • , N. Vijay Kamasewara Rao
  • , Zih Yao Yu
  • , Ram Sharma
  • , Jacob Mathew
  • , Yu Wen Chen
  • , Sung Bau Lee
  • , Ankush Bansode
  • , Tai Ju Hsu
  • , Ajmer Singh Grewal
  • , Chun Hsu Pan
  • , Santosh Guru
  • , Kunal Nepali

Research output: Contribution to journal › Article › peer-review

Abstract

Tempted by the clinical outcomes attained with the combination of poly(ADP-ribose) polymerase (PARP) and vascular endothelial growth factor receptor (VEGFR) inhibitors, a compendium of dual PARP-VEGFR inhibitory assemblages based on structural commonalities of Olaparib (PARP inhibitor) and Cediranib (VEGFR inhibitor) was furnished. The aforementioned efforts culminated into a strikingly potent antitumor agent 18 exerting remarkable cell growth inhibitory effects [IC50 = 0.37 μM (HL60); 0.56 μM (A549); 0.80 μM (MDA-MB-231)] through a balanced inhibition of PARP and VEGFR. Specifically, 18 displayed magnificent PARP1, PARP2, and VEGFR3 inhibitory profiles with an IC50 value of 0.0763 nM, 0.0366 nM, and 4.25 nM, respectively. Further, a charge-convertible polymer-based nanoformulation (18-PEG-PLL/DMMA nanoparticles) for targeted drug delivery of 18 was developed. Encouragingly, the nanoformulation demonstrated a cytotoxicity-devoid profile towards normal cells owing to its pH-sensitive behavior and manifested selective cell growth inhibition against solid tumor cells, possibly due to the EPR effect.

Original languageEnglish
Article number109035
JournalBioorganic Chemistry
Volume165
DOIs
Publication statusPublished - Oct 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Leukemia
  • Lung cancer
  • Nanoformulation
  • PARP inhibitors
  • VEGFR inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Drug Discovery
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Olaparib-Cediranib Hybrid as Dual PARP-VEGFR3 Inhibitor Elicits Antitumor Efficacy: Rational Design, Synthesis, Biological Evaluation and Construction of a Charge Convertible pH Responsive Nanoformulation'. Together they form a unique fingerprint.

Cite this